{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T12:00:16Z","timestamp":1694260816622},"reference-count":46,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Interventional Cardiology Clinics"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1016\/j.iccl.2013.05.010","type":"journal-article","created":{"date-parts":[[2013,7,10]],"date-time":"2013-07-10T20:45:55Z","timestamp":1373489155000},"page":"527-535","source":"Crossref","is-referenced-by-count":2,"title":["Aspirin, Platelet P2Y12 Receptor Inhibitors, and Other Oral Antiplatelets"],"prefix":"10.1016","volume":"2","author":[{"given":"Vijay","family":"Kunadian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah","family":"Sinclair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron","family":"Sutton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George D.","family":"Dangas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.iccl.2013.05.010_bib1","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1161\/CIR.0b013e31823ac046","article-title":"Heart disease and stroke statistics: 2012 update","volume":"125","author":"Roger","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.iccl.2013.05.010_bib2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJM199101033240103","article-title":"Angiographic follow-up after placement of a self-expanding coronary-artery stent","volume":"324","author":"Serruys","year":"1991","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.iccl.2013.05.010_bib3","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1161\/01.RES.0000264509.36234.51","article-title":"Clinical aspects of platelet inhibitors and thrombus formation","volume":"100","author":"Meadows","year":"2007","journal-title":"Circ Res"},{"key":"10.1016\/j.iccl.2013.05.010_bib4","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1161\/01.ATV.0000145980.39477.a9","article-title":"Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance","volume":"24","author":"Cattaneo","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.iccl.2013.05.010_bib5","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1161\/01.CIR.69.4.721","article-title":"Coumadin and aspirin in prevention of recurrence after transluminal coronary angioplasty: a randomized study","volume":"69","author":"Thornton","year":"1984","journal-title":"Circulation"},{"key":"10.1016\/j.iccl.2013.05.010_bib6","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.iccl.2013.05.010_bib7","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1136\/bmj.310.6983.827","article-title":"Prophylactic aspirin and risk of peptic ulcer bleeding","volume":"310","author":"Weil","year":"1995","journal-title":"BMJ"},{"key":"10.1016\/j.iccl.2013.05.010_bib8","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1161\/01.CIR.100.15.1667","article-title":"Ticlopidine and clopidogrel","volume":"100","author":"Quinn","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.iccl.2013.05.010_bib9","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1056\/NEJM199812033392303","article-title":"A\u00a0clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent anticoagulation restenosis study investigators","volume":"339","author":"Leon","year":"1998","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.iccl.2013.05.010_bib10","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1161\/01.CIR.98.16.1597","article-title":"Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study","volume":"98","author":"Bertrand","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.iccl.2013.05.010_bib11","first-page":"462","article-title":"Restenosis after coronary stent placement and randomization to a 4-week combined antiplatelet or anticoagulant therapy: six-month angiographic follow-up of the intracoronary stenting and antithrombotic regimen (ISAR) trial","volume":"96","author":"Kastrati","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.iccl.2013.05.010_bib12","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1161\/01.CIR.98.20.2126","article-title":"Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (mattis)","volume":"98","author":"Urban","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.iccl.2013.05.010_bib13","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1136\/pgmj.74.868.126","article-title":"Ticlopidine-induced severe neutropaenia","volume":"74","author":"Gur","year":"1998","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.iccl.2013.05.010_bib14","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/01.CIR.102.6.624","volume":"102","author":"Bertrand","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.iccl.2013.05.010_bib15","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0735-1097(01)01713-2","article-title":"Meta-analysis\u00a0of randomized and registry comparisons of ticlopidine with clopidogrel after stenting","volume":"39","author":"Bhatt","year":"2002","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.iccl.2013.05.010_bib16","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","article-title":"Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial","volume":"288","author":"Steinhubl","year":"2002","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.iccl.2013.05.010_bib17","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.amjcard.2010.08.035","article-title":"Comparison of adverse cardiovascular events and bleeding complications of loading dose of clopidogrel 300 mg versus 600 mg in stable patients undergoing elective percutaneous intervention (from the CADICE study)","volume":"107","author":"Fernandez","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.iccl.2013.05.010_bib18","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jacc.2004.09.067","article-title":"Variability in platelet responsiveness to clopidogrel among 544 individuals","volume":"45","author":"Serebruany","year":"2005","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.iccl.2013.05.010_bib19","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1016\/j.jacc.2005.07.056","article-title":"Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST study","volume":"46","author":"Gurbel","year":"2005","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.iccl.2013.05.010_bib20","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nm.2281","article-title":"Paraoxonase-1 is a major determinant of clopidogrel efficacy","volume":"17","author":"Bouman","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.iccl.2013.05.010_bib21","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/j.jacc.2007.12.056","article-title":"Cytochrome p450 2c19 681g>a polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents","volume":"51","author":"Trenk","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.iccl.2013.05.010_bib22","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jacc.2007.01.097","article-title":"Lack of evidence of a clopidogrel-statin interaction in the charisma trial","volume":"50","author":"Saw","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.iccl.2013.05.010_bib23","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1007964","article-title":"Clopidogrel with or without omeprazole in coronary artery disease","volume":"363","author":"Bhatt","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.iccl.2013.05.010_bib24","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1001\/jama.2011.290","article-title":"Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the gravitas randomized trial","volume":"305","author":"Price","year":"2011","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.iccl.2013.05.010_bib25","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1038\/sj.bjp.0703237","article-title":"The in\u00a0vivo pharmacological profile of cs-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties","volume":"129","author":"Sugidachi","year":"2000","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.iccl.2013.05.010_bib26","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1161\/CIRCULATIONAHA.104.502815","article-title":"Randomized comparison of prasugrel (cs-747, ly640315), a novel thienopyridine p2y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the joint utilization of medications to block platelets optimally (jumbo)-TIMI 26 trial","volume":"111","author":"Wiviott","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.iccl.2013.05.010_bib27","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1016\/j.jacc.2012.02.026","volume":"59","author":"Trenk","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.iccl.2013.05.010_bib28","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1161\/CIRCULATIONAHA.107.740324","volume":"116","author":"Wiviott","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.iccl.2013.05.010_bib29","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/eurheartj\/ehi754","article-title":"Pharmacodynamics, pharmacokinetics, and safety of the oral reversible p2y12 antagonist azd6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin","volume":"27","author":"Husted","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.iccl.2013.05.010_bib30","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.iccl.2013.05.010_bib31","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1056\/NEJMoa0908628","article-title":"Platelet inhibition with cangrelor in patients undergoing PCI","volume":"361","author":"Harrington","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.iccl.2013.05.010_bib32","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1001\/jama.2011.2002","article-title":"Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial","volume":"307","author":"Angiolillo","year":"2012","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.iccl.2013.05.010_bib33","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1056\/NEJMoa1300815","article-title":"Effect of platelet inhibition with cangrelor during PCI on ischemic events","volume":"368","author":"Bhatt","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.iccl.2013.05.010_bib34","first-page":"445","article-title":"Elinogrel: pharmacological principles, preclinical and early phase clinical testing","volume":"6","author":"Ueno","year":"2010","journal-title":"Futures"},{"key":"10.1016\/j.iccl.2013.05.010_bib35","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1161\/CIRCINTERVENTIONS.111.964197","volume":"5","author":"Welsh","year":"2012","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.iccl.2013.05.010_bib36","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1016\/j.jacc.2007.01.094","article-title":"Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis","volume":"49","author":"Buonamici","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.iccl.2013.05.010_bib37","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/j.jacc.2006.11.044","article-title":"Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives","volume":"49","author":"Angiolillo","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.iccl.2013.05.010_bib38","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1016\/j.jacc.2011.11.068","article-title":"Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: the GIFT (genotype information and functional testing) study","volume":"59","author":"Price","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.iccl.2013.05.010_bib39","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/j.1538-7836.2009.03733.x","article-title":"Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel","volume":"8","author":"Bouman","year":"2010","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.iccl.2013.05.010_bib40","doi-asserted-by":"crossref","first-page":"e130","DOI":"10.1016\/j.thromres.2011.07.028","article-title":"Determination of cut-off levels for on-clopidogrel platelet aggregation based on functional cyp2c19 gene variants in patients undergoing elective percutaneous coronary intervention","volume":"128","author":"Ono","year":"2011","journal-title":"Thromb Res"},{"key":"10.1016\/j.iccl.2013.05.010_bib41","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.jcin.2012.01.009","volume":"5","author":"Mangiacapra","year":"2012","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.iccl.2013.05.010_bib42","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ijcard.2011.12.046","article-title":"Quantitative comparison of clopidogrel 600 mg, prasugrel and ticagrelor, against clopidogrel 300 mg on major adverse cardiovascular events and bleeding in coronary stenting: synthesis of current-oasis-7, triton-timi-38 and plato","volume":"158","author":"Nijjer","year":"2012","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.iccl.2013.05.010_bib43","doi-asserted-by":"crossref","DOI":"10.1007\/s11239-013-0876-1","article-title":"Mean platelet volume as a predictor for long-term outcome after percutaneous coronary intervention","author":"Eisen","year":"2013","journal-title":"J\u00a0Thromb Thrombolysis"},{"key":"10.1016\/j.iccl.2013.05.010_bib44","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jacc.2008.05.031","article-title":"Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease","volume":"52","author":"Guthikonda","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.iccl.2013.05.010_bib45","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/MBC.0b013e328358e941","article-title":"Short-term effects of aspirin and clopidogrel on mean platelet volume among patients with acute coronary syndromes. A single-center prospective study","volume":"23","author":"De Luca","year":"2012","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.iccl.2013.05.010_bib46","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jacc.2012.09.037","article-title":"Elevated plasma fibrinogen rather than residual platelet reactivity after clopidogrel pre-treatment is associated with an increased ischemic risk during elective percutaneous coronary intervention","volume":"61","author":"Ang","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"}],"container-title":["Interventional Cardiology Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211745813000515?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211745813000515?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,14]],"date-time":"2018-10-14T13:28:17Z","timestamp":1539523697000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211745813000515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S2211745813000515"],"URL":"https:\/\/doi.org\/10.1016\/j.iccl.2013.05.010","relation":{},"ISSN":["2211-7458"],"issn-type":[{"value":"2211-7458","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]}}}